This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (71)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Thrombolysis  • Venous Thromboembolism  • Cardiovascular System  • Review  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

A Systematic Review

Wendy Lim, MD; Mark A. Crowther, MD; John W. Eikelboom, MBBS

JAMA. 2006;295:1050-1057.

Context  Antiphospholipid antibodies are autoantibodies directed against proteins that bind to phospholipid. Antiphospholipid antibody syndrome (APS) refers to the association between antiphospholipid antibodies and thrombosis risk or pregnancy morbidity. Patients with APS may be at increased risk of recurrent arterial or venous thrombosis or pregnancy loss.

Objective  To systematically review the evidence for treatment of thrombosis risk in patients with antiphospholipid antibodies or APS.

Evidence Acquisition  Search of MEDLINE (1966 to November 2005) and Cochrane Library electronic databases (2005) and reference lists for randomized trials, meta-analyses of randomized trials, and prospective cohort studies of the treatment of thrombosis risk in patients with antiphospholipid antibodies or APS. Studies were selected on the basis of clinical relevance.

Evidence Synthesis  Among patients with antiphospholipid antibodies, the absolute risk of developing new thrombosis is low (<1% per year) in otherwise healthy patients without prior thrombotic events, may be moderately increased (up to 10% per year) in women with recurrent fetal loss without prior thrombosis, and is highest (>10% in the first year) in patients with a history of venous thrombosis who have discontinued anticoagulant drugs within 6 months. Compared with placebo or untreated control, anticoagulation with moderate-intensity warfarin (adjusted to a target international normalized ratio [INR] of 2.0-3.0) reduces the risk of recurrent venous thrombosis by 80% to 90% irrespective of the presence of antiphospholipid antibodies and may be effective for preventing recurrent arterial thrombosis. No evidence exists that high-intensity warfarin (target INR, >3.0) is more effective than moderate-intensity warfarin. For patients with a single positive antiphospholipid antibody test result and prior stroke, aspirin and moderate-intensity warfarin appear equally effective for preventing recurrent stroke. Treatment issues that have not been addressed in clinical trials, or for which the evidence is conflicting, include the role of antithrombotic prophylaxis in patients with antiphospholipid antibodies without prior thrombosis, the optimal treatment of noncerebrovascular arterial thrombosis, recurrent thrombosis despite warfarin therapy, and treatment of women with antiphospholipid antibodies and recurrent fetal loss.

Conclusions  In patients with APS, moderate-intensity warfarin is effective for preventing recurrent venous thrombosis and perhaps also arterial thrombosis. Aspirin appears to be as effective as moderate-intensity warfarin for preventing recurrent stroke in patients with prior stroke and a single positive test result for antiphospholipid antibody. The optimal treatment of other thrombotic aspects of APS needs to be addressed in well-designed prospective studies.

Author Affiliations: Department of Medicine, McMaster University, Hamilton, Ontario.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Treatment of Antiphospholipid Antibody Syndrome
Denis Wahl and Veronique Regnault
JAMA. 2006;296(1):42-43.
EXTRACT | FULL TEXT  

Treatment of Antiphospholipid Antibody Syndrome—Reply
Wendy Lim, Mark Crowther, and John Eikelboom
JAMA. 2006;296(1):43.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-{beta}2-glycoprotein I complexes to phospholipid bilayers
Rand et al.
Blood 2008;112:1687-1695.
ABSTRACT | FULL TEXT  

Venous thromboembolism in women
Rathbun
Vasc Med 2008;13:255-266.
ABSTRACT  

Antiphospholipid syndrome dilemmas still to be solved: 2008 status
Shoenfeld et al.
Ann Rheum Dis 2008;67:438-442.
FULL TEXT  

Lupus: improving long-term prognosis
Doria and Briani
Lupus 2008;17:166-170.
ABSTRACT  

Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature
Erre et al.
Lupus 2008;17:50-55.
ABSTRACT  

A 29-Year-Old Man With Pulmonary Complications of a Thrombotic Disorder
Rose and Sajkov
Chest 2007;132:2008-2011.
FULL TEXT  

How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review
Garcia et al.
Blood 2007;110:3122-3127.
ABSTRACT | FULL TEXT  

Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome
Avcin and Silverman
Lupus 2007;16:627-633.
ABSTRACT  

Perinatal Implications of the Antiphospholipid Syndrome
Smith and Druzin
NeoReviews 2007;8:e206-e213.
ABSTRACT | FULL TEXT  

Proposed Relationship Between Intravenous Immunoglobulin and Thrombosis in Renal Transplant Recipients
Duronio et al.
The Annals of Pharmacotherapy 2007;41:354-358.
ABSTRACT | FULL TEXT  

The Antiphospholipid Syndrome
Rand
ASH Education Book 2007;2007:136-142.
ABSTRACT | FULL TEXT  

Hemostasis and thrombosis
Crowther and Abshire
ASH-SAP 2007;2007:361-407.
FULL TEXT  

Consultative hematology
McCrae et al.
ASH-SAP 2007;2007:466-505.
FULL TEXT  

Acute Pulmonary Embolism: Part I: Epidemiology and Diagnosis
Piazza and Goldhaber
Circulation 2006;114:e28-e32.
FULL TEXT  

Treatment of antiphospholipid antibody syndrome.
Wahl and Regnault
JAMA 2006;296:42-43.
FULL TEXT  

Thrombosis in Infants and Children
Schneppenheim and Greiner
ASH Education Book 2006;2006:86-96.
ABSTRACT | FULL TEXT